Of note, our drug sensitivity analysis showed that SLC43A1 overexpression sensitizes cancer cell lines to Nilotinib, Palbociclib (PD0332991), Crizotinib (PF2341066), and γ-secretase inhibitor (L685458). The gene discussed is SLC43A1; the disease is cancer.